ArticleClinical research in cardiology : official journal of the German Cardiac Society2026
Predicting atrial fibrillation after an acute coronary syndrome: insights from the BACS & BAMI study.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtrial fibrillation (AF) is among the most prevalent arrhythmias. Its onset after an acute coronary syndrome (ACS) is especially notable given the high coronary disease burden. Mineral metabolism, particularly fibroblast growth factor 23 (FGF23), has been linked to cardiovascular outcomes. This study examines whether FGF23, related markers and other variables can predict AF occurrence after an ACS, considering age differences.
methodsData were obtained from the BACS & BAMI study, including 1189 patients from five Madrid hospitals. Baseline clinical characteristics and laboratory results were recorded. Patients were monitored annually through clinical appointments. Univariate and multivariate Cox analyses were conducted separately for patients aged ≤ 65 and > 65 years, based on CHA2DS2-VA thromboembolic score.
resultsOver a follow-up of 5.44 (3.03-7.46) years, 5.5% of patients developed AF. In those ≤ 65 years, FGF23 was an independent predictor of the development of AF (HR 1.37 [1.04, 1.79] per 100-unit rise; p = 0.026). Among patients > 65 years, a history of stroke was associated with a heightened risk (HR 2.75 [1.03, 7.34]; p = 0.044), while beta-blocker therapy appeared to be protective (HR 0.42 [0.23, 0.78]; p = 0.007). Previous AF consistently forecasted recurrence across both groups (HR 11.3 [2.92, 43.6]; p = 0.002 and HR 6.41 [3.13, 13.1]; p < 0.001, respectively).
conclusionsFGF23 seems to be an independent and positive predictor of AF after an ACS in patients ≤ 65 years, whereas in older individuals, beta-blocker therapy emerges as a potential protective measure. These insights may enhance current risk models with age-specific adjustments and encourage more tailored clinical strategies in post-ACS patients.
Indexed as
Identifiers
42008145What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.